Gynaecomastia: The Anastrozole Paradox

  title={Gynaecomastia: The Anastrozole Paradox},
  author={D. Bedognetti and A. Rubagotti and G. Zoppoli and F. Boccardo},
  journal={Journal of Pediatric Endocrinology and Metabolism},
  pages={205 - 206}
  • D. Bedognetti, A. Rubagotti, +1 author F. Boccardo
  • Published 2010
  • Medicine
  • Journal of Pediatric Endocrinology and Metabolism
  • Recently, Mauras et al. published the results of a clinical trial evaluating the pharmacokinetics of oral anastrozole (an aromatase inhibitor) in adolescent males with gynaecomastia. The authors evaluated 42 boys (11-15 years old) with early onset gynaecomastia (4:5-10.5 months) treated with anastrozole (1 mg daily) for 6 months. Mauras and coworkers found that anastrozole had rapid absorption and slow elimination kinetics, and caused testosterone/oestradiol to increase, proving its aromatase… CONTINUE READING
    1 Citations
    Drug‐Induced Gynecomastia
    • 24


    Pharmacokinetics and pharmacodynamics of anastrozole in pubertal boys with recent-onset gynecomastia.
    • 34
    • PDF
    Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
    • 95
    The Effect of Tamoxifen on Sex Hormone Binding Globulin in Adolescents with Pubertal Gynecomastia
    • 10
    Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebocontrolled trial
    • J Clin Hndocrinol Metab
    • 2004